Researchers at Cincinnati Children’s have created a breakthrough method for producing large, nerve-equipped human gut organoids in half the time of previous techniques. The advance could accelerate transplant therapies for patients with damaged digestive organs.
Scientists at Cincinnati Children’s Hospital Medical Center have developed a new way to grow miniature human gut organs that are larger, faster to produce, and capable of generating their own nerve cells — a combination of advances that brings lab-grown tissue transplants meaningfully closer to clinical reality.
The research, published May 22 in Nature Biomedical Engineering, centers on a novel “confined culture system” (CCS) built around 3D-printed scaffolding trays. Those trays guide clusters of stem-cell-derived spheroids to fuse and mature into centimeter-scale tubular structures — organs roughly 10 times larger than what older protocols could yield, achieved in just 14 days instead of 28.
How the New System Works
The scaffolding trays are fabricated from surgical resin and then filled with a flexible, rubber-like silicone called polydimethylsiloxane. The trays’ grooves align rows of tiny spherical organoids, coaxing them to merge and mature within a nutrient-rich medium derived from induced pluripotent stem cells (iPSCs). By day six, the individual spheroids fuse into unified structures. By day 14, those constructs contain the full range of cell types that previously took four weeks to develop.
After that initial growth phase, researchers transplanted the organoids into genetically modified rodents designed to minimize rejection. Every transplanted tissue successfully engrafted. Once inside the animals, the tissues expanded to produce as much as 8 centimeters of functioning small intestine — compared with roughly 1 centimeter using earlier methods.
Crucially, the new organoids also developed a functional nervous system on their own, without the complex external steps previously required to introduce nerve cells. Lead author Holly Poling, a staff investigator at Cincinnati Children’s, described the achievement as a convergence of biology and engineering.
“By reaching transplantation maturity twice as fast and developing their own functional nerves, these organoids demonstrate how engineering principles can drive biological innovation,” Poling said in a news release. “Our confined culture system is more than a production method; it’s a scalable, flexible platform for building complex human tissues.”
Self-Organizing Nerves Are a Big Deal
The spontaneous emergence of an enteric nervous system — the network of neurons that governs gut movement and function — is arguably the most significant scientific leap in the new work. Senior author Maxime Mahe, an adjunct assistant professor in the Division of Pediatric General and Thoracic Surgery at Cincinnati Children’s, noted that the team can now not only scale production but also shape how those tissues mature.
“We are now able not only to generate complex gastrointestinal organoids at scale, but also to guide their differentiation into functional tissues with integrated enteric neuronal networks,” Mahe said in the news release. “By leveraging a defined growth environment, the intrinsic self-organization capacity of the cells drives the formation of tissue structures that closely resemble the human gastrointestinal tract.”
Co-author Jim Wells, the chief scientific director at Cincinnati Children’s Center for Stem Cell & Organoid Medicine (CuSTOM), highlighted both the practical and scientific implications of that self-organized nervous system.
“This platform’s simplicity, reproducibility, and versatility make it accessible for widespread adoption,” Wells said. “In addition, the emergence of a self-organized nervous system within these organoids is particularly important for further studies of neurodevelopmental disorders.”
Why It Matters for Patients
Cincinnati Children’s has been refining digestive-organ organoids for more than 15 years. The immediate goal is generating enough patient-matched tissue to repair or replace sections of damaged intestine, stomach or colon — conditions that disproportionately affect infants and children born with underdeveloped or dysfunctional digestive systems.
Co-senior author Michael Helmrath, a surgeon-scientist who co-directs CuSTOM and has spent over a decade moving intestinal organoids toward the operating room, offered a measured but optimistic assessment.
“It is still not possible to grow complete, full-sized human organs in some sort of tank, but research like this has produced significant amounts of tissue that can be matched directly to individual patients,” Helmrath said. “We believe such tissues, once transplanted, would further grow and multiply as part of the patient’s own organ to restore functions.”
More development work is required before CCS organoids enter human clinical trials, Helmrath acknowledged. But if progress continues, organoid medicine could eventually spare many young patients from the need for a full organ transplant altogether.
What This Means for Medical Research
Beyond transplantation, larger and more physiologically accurate gut organoids have immediate value for basic science. Researchers studying inflammatory bowel disease, short bowel syndrome, or the intestinal side effects of oral medications would gain a far more realistic tissue model to work with. The self-organized nerve networks also open new doors for studying conditions like Hirschsprung disease, a congenital disorder in which nerve cells are absent from parts of the colon.
The study was co-authored by a team of scientists from Cincinnati Children’s and Nantes Université in France.